Financial Performance - Old National's net income applicable to common shareholders for 2025 was $653.1 million, or $1.79 per diluted common share, with adjusted net income of $808.6 million, or $2.21 per diluted common share [230][231]. - Net income available to common shareholders was $653,122, a 24.8% increase from $523,053 in 2024 [239]. - The diluted net income per common share increased to $1.79 in 2025 from $1.68 in 2024, a rise of 6.5% [251]. - The company reported a return on average assets of 1.21% and a return on average common equity of 10.44% for the fourth quarter of 2025 [237]. - The return on average tangible common equity was 15.27%, slightly down from 15.37% in 2024 [239]. Growth and Acquisitions - Total deposits grew by 35% in 2025, with a loan-to-deposit ratio of 89% [230]. - Old National completed its acquisition of Bremer on May 1, 2025, enhancing its operating platform [233]. - Total loans reached $48.76 billion by December 31, 2025, up from $36.29 billion a year earlier [237]. - Total assets increased to $72,151,967, up 34.7% from $53,552,272 in the previous year [239]. - The company expanded its workforce to 4,971 full-time equivalent employees, an increase from 4,066 in the previous year [239]. Income and Revenue - Net interest income increased by 34% to $2.1 billion, driven by strong loan growth and the Bremer acquisition [232]. - Noninterest income rose from $354.7 million in 2024 to $466.5 million in 2025, primarily due to the Bremer acquisition and higher mortgage banking revenue [232]. - Noninterest income grew to $466,531 in 2025, compared to $354,697 in 2024, marking a 31.5% increase [251]. - The company reported a total interest income increase of $672,099 thousand from 2024 to 2025, attributed to strong loan growth and higher average balances [260]. Efficiency and Management - The efficiency ratio improved to 55.10%, reflecting disciplined expense management [230]. - The efficiency ratio improved to 55.10%, down from 55.85% in 2024, indicating better cost management [239]. - Total noninterest expense increased to $1.5 billion in 2025, a 35.7% rise from 2024, including $140.9 million of merger-related expenses [272]. Credit and Loan Quality - Provision for credit losses increased to $197,721, compared to $110,619 in 2024, reflecting a rise of 78.5% [239]. - The allowance for credit losses on loans increased to $569.5 million at December 31, 2025, up from $392.5 million at December 31, 2024, reflecting adjustments related to the Bremer acquisition [297]. - Total charge-offs for 2025 amounted to $125.0 million, significantly higher than $71.3 million in 2024 [332]. - The net charge-off ratio for commercial loans was 0.46% in 2025, up from 0.35% in 2024, indicating a rise in credit losses [333]. Asset Management - The tangible common equity to tangible assets ratio improved to 7.72% in 2025 from 7.41% in 2024, indicating stronger capital efficiency [249]. - The investment securities portfolio increased to $14.9 billion at December 31, 2025, compared to $10.9 billion at December 31, 2024, primarily due to the Bremer acquisition [279]. - Total funding increased by $16.3 billion to $62.5 billion at December 31, 2025, reflecting both deposit growth and wholesale borrowings [302]. Regulatory and Compliance - The effective tax rate was 20.5% in 2025, slightly down from 20.8% in 2024, influenced by tax benefits from tax credit investments [275]. - Old National's credit ratings are Baa1 for long-term and A1 for short-term from Moody's Investors Service as of December 31, 2025 [354]. - Compliance and regulatory risk management is embedded in the company's culture, with oversight from multiple lines of defense [359]. Future Outlook - Looking ahead, Old National aims for continued organic growth and investment in technology and talent [235]. - Projected net interest income for December 31, 2025, is estimated at $9,050,648 thousand, reflecting a year-over-year increase driven by loan growth and asset repricing [344].

Financial Performance - Old National's net income applicable to common shareholders for 2025 was $653.1 million, or $1.79 per diluted common share, with adjusted net income of $808.6 million, or $2.21 per diluted common share [230][231]. - Net income available to common shareholders increased to $653,122, reflecting a 24.8% growth compared to $523,053 in 2024 [239]. - The return on average common equity for Q4 2025 was 10.44%, up from 9.01% in Q3 2025 [237]. - Diluted net income per common share increased to $1.79 in 2025 from $1.68 in 2024, a growth of 6.5% [251]. - The effective tax rate was 20.5% in 2025, slightly down from 20.8% in 2024, influenced by tax benefits from tax credit investments [275]. Growth and Acquisitions - The completion of the Bremer acquisition on May 1, 2025, solidified Old National's position as a premier mid-size bank [230][233]. - Total deposits grew by 35% in 2025, with a loan-to-deposit ratio of 89% [230]. - The company plans to focus on disciplined organic growth and continued investment in technology and client-facing capabilities in 2026 [235]. - The company's assets grew to $72.2 billion at December 31, 2025, an increase of $18.6 billion from $53.6 billion at December 31, 2024, mainly due to the Bremer acquisition [276]. Income and Expenses - Net interest income increased by 34% to $2.1 billion, driven by strong loan growth and the Bremer acquisition [232]. - Noninterest income rose from $354.7 million in 2024 to $466.5 million in 2025, primarily due to the Bremer acquisition and higher mortgage banking revenue [232]. - Total noninterest expense reached $1.5 billion in 2025, a 35.7% increase from 2024, including $140.9 million of merger-related expenses [272]. - The total interest expense for 2025 was $1,211,979 thousand, compared to $1,070,868 thousand in 2024 [260]. Asset and Loan Growth - Old National's total loans reached $48.76 billion by December 31, 2025, up from $36.29 billion a year earlier [237]. - Total loans grew significantly to $48,764,162, a 34.4% increase from $36,285,887 in 2024 [239]. - Average loans, including loans held-for-sale, increased by $8.7 billion in 2025, primarily due to the acquisition of Bremer loans totaling $11.1 billion [265]. - The loan portfolio totaled $48.8 billion at December 31, 2025, reflecting a 34.4% increase from $36.3 billion at December 31, 2024 [283]. Capital and Equity - Shareholders' equity reached $8.5 billion, or 12% of total assets, at December 31, 2025, up from $6.3 billion at December 31, 2024, due to equity raised from the Bremer acquisition [305]. - Tangible book value per share grew by 15% in 2025, with a focus on driving further growth in 2026 [230][234]. - The tangible common book value per share rose to $13.71, compared to $11.91 in 2024, reflecting improved capital strength [239]. Credit Quality and Losses - Provision for credit losses increased to $197,721 in 2025, up from $110,619 in 2024, reflecting a rise of 78.5% [251]. - The allowance for credit losses on loans increased to $569.5 million at December 31, 2025, up from $392.5 million at December 31, 2024, reflecting adjustments related to the Bremer acquisition [297]. - Total charge-offs for the year 2025 amounted to $125.0 million, significantly higher than $71.3 million in 2024 [332]. - The net charge-offs to average loans ratio for total loans was 0.25% in 2025, compared to 0.17% in 2024, indicating a deterioration in credit quality [333]. Operational Metrics - The efficiency ratio improved to 55.10%, reflecting disciplined expense management [230]. - The efficiency ratio improved to 55.10%, down from 55.85% in 2024, indicating better cost management [239]. - The number of full-time equivalent employees increased to 4,971, up from 4,066 in 2024, indicating growth in operational capacity [239]. Risk Management - The company maintains frameworks to mitigate operational risks, including cybersecurity threats and internal control weaknesses [358]. - Compliance and regulatory risks are managed through established policies and oversight to ensure adherence to applicable laws and regulations [359]. - Legal risks are addressed through corporate governance practices that comply with legal requirements and market standards [360].

Financial Performance - Old National's net income applicable to common shareholders for 2025 was $653.1 million, or $1.79 per diluted common share, with adjusted net income of $808.6 million, or $2.21 per diluted common share [230][231]. - Net income available to common shareholders was $653,122 in 2025, a 24.8% increase from $523,053 in 2024 [239]. - The diluted net income per common share increased to $1.79 in 2025, compared to $1.68 in 2024, a rise of 6.5% [251]. - The return on average common equity for Q4 2025 was 10.44%, up from 9.83% in Q4 2024 [237]. - The return on average tangible common equity was 15.27% in 2025, slightly down from 15.37% in 2024 [239]. Growth and Acquisitions - Total deposits grew by 35% in 2025, with a loan to deposit ratio of 89% [230]. - Old National completed its acquisition of Bremer on May 1, 2025, enhancing its operating platform [233]. - The total loans increased to $48.76 billion by December 31, 2025, up from $36.29 billion a year earlier [237]. - Total assets grew to $72,151,967 in 2025, compared to $53,552,272 in 2024, an increase of 34.7% [239]. - The company's assets grew to $72.2 billion at December 31, 2025, an increase of $18.6 billion from $53.6 billion at December 31, 2024, mainly due to the acquisition of Bremer [276]. Income and Expenses - Net interest income increased by 34% to $2.1 billion, driven by strong loan growth and the Bremer acquisition [232]. - Noninterest income rose from $354.7 million in 2024 to $466.5 million in 2025, primarily due to the Bremer acquisition and higher mortgage banking revenue [232]. - Total noninterest expense increased to $1.5 billion in 2025, a 35.7% rise from 2024, including $140.9 million of merger-related expenses [272]. - The efficiency ratio improved to 55.10%, reflecting disciplined expense management [230]. Credit Quality and Losses - Provision for credit losses increased to $197,721 in 2025, up from $110,619 in 2024, reflecting a significant rise in credit risk [239]. - The allowance for credit losses on loans increased to $569.5 million at December 31, 2025, up from $392.5 million at December 31, 2024, reflecting adjustments related to the Bremer acquisition [297]. - Total provision for credit losses increased by $87.1 million in 2025 compared to 2024, reaching $197.7 million, primarily due to credit migration and macroeconomic factors [267]. - The net charge-off ratio for commercial loans was 0.46% in 2025, compared to 0.35% in 2024, indicating a rise in credit losses [333]. Deposits and Funding - Total deposits grew by $14.3 billion to $55.1 billion at December 31, 2025, attributed to Bremer deposits and organic growth [302]. - Total funding increased by $16.3 billion to $62.5 billion at December 31, 2025, reflecting both deposit growth and wholesale borrowings [302]. - The estimated amount of FDIC uninsured deposits for regulatory purposes was $23.7 billion at December 31, 2025 [303]. Operational Metrics - Full-time equivalent employees increased to 4,971 in 2025, up from 4,066 in 2024, reflecting expansion in operations [239]. - The average loans for the year increased to $44.22 billion in 2025 from $35.51 billion in 2024, reflecting growth in the loan portfolio [333]. - The average commercial loan size was approximately $771,000, while the average commercial real estate loan size was approximately $1.5 million as of December 31, 2025 [322]. Risk Management - The company is focused on managing interest rate risk to maximize net interest income while maintaining adequate funding and liquidity [340]. - Compliance and regulatory risk management is embedded in the company culture, ensuring adherence to applicable laws and regulations [359]. - The company maintains frameworks to manage operational risks, including cybersecurity threats and internal control weaknesses [358]. Tax and Legal Considerations - The effective tax rate was 20.5% in 2025, slightly down from 20.8% in 2024, influenced by tax benefits from tax credit investments [275]. - The company reviews income tax expense and deferred tax assets quarterly, with potential material impacts from tax law interpretations and disputes [378].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission file number: 001-38762 BIOMX INC. (Exact name of registrant as specified in its charter) | Delaware | 82-3364020 | | --- | --- | | (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.) Form 20-F x Form 40-F o _______________________________ FORM 6-K _______________________________ REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2026 Commission File No. 001-37596 _______________________________ FERRARI N.V. (Translati ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 or ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report or For the transition period from: to Commission file number: 001-10533 Commission file number: 001-34121 Rio Tinto plc Rio Tinto Limited ABN 96 004 458 404 (Mark One) For the fiscal year ended: ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________ Form 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-13831 Quanta Services, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...

Financial Performance - Net sales for 2025 were $5.3 billion, consistent with 2024, indicating stability in maintenance sales and growth in building materials in the latter half of the year[5]. - Gross margin remained at 29.7% for both 2025 and 2024, with a 20 basis points improvement in 2025 when excluding the 2024 import tax reversal[6]. - Operating income decreased by 6% to $580.2 million in 2025 compared to $617.2 million in 2024[8]. - Net income for 2025 was $406.4 million, down from $434.3 million in 2024, reflecting a decrease of 6%[8]. - Diluted EPS for 2025 was $10.85, a decline of 4% from $11.30 in 2024, which included a $0.25 benefit from the import tax reversal[10]. - Adjusted EBITDA for 2025 was $654,344, down from $680,856 in 2024, reflecting a decrease of approximately 4%[37]. - Adjusted diluted EPS for 2025 was $10.73, down from $11.07 in 2024, a decrease of approximately 3%[41]. Cash Flow and Working Capital - Net cash provided by operations was $365.9 million in 2025, significantly lower than $659.2 million in 2024, primarily due to working capital investments[12]. - Net cash provided by operating activities decreased significantly by 44% to $365,850 from $659,186 in 2024[27]. - Cash and cash equivalents at the end of the period increased by 35% to $104,963, compared to $77,862 in 2024[27]. Debt and Liabilities - Total debt outstanding rose by $249.1 million to $1.2 billion, primarily to fund share repurchases of $341.1 million in 2025[11]. - Long-term debt increased by 32% to $1,186,424, up from $900,883 in 2024[25]. - Accounts payable rose by 24% to $652,619, compared to $525,235 in 2024[25]. Inventory and Assets - Inventory balance increased by 13% to $1.5 billion as of December 31, 2025, driven by increased purchasing ahead of price increases and inflation[11]. - Total assets increased by 8% to $3,626,126, up from $3,368,184 in 2024, with current assets rising by 14% to $1,969,864[25]. Company Operations - The company operates 456 sales centers globally, distributing over 200,000 products to approximately 125,000 wholesale customers[19]. - The company acquired 3 new locations and opened 8 new locations, resulting in a total of 456 sales centers by December 31, 2025[31]. Future Outlook - For 2026, the company expects diluted EPS to be in the range of $10.85 to $11.15, reflecting expectations for modest sales growth and improved earnings[9][16]. Impairments - The company reported a goodwill impairment of $285 in 2025, with no such impairment reported in 2024[37].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38466 GOOSEHEAD INSURANCE, INC. (Exact name of registrant as specified in its charter) Delaware 82-3886022 (State or other jurisdiction of incorpor ...

Financial Performance - The company has an accumulated deficit of $2,090.5 million as of December 31, 2025, and has incurred losses since inception [422]. - Product revenue for the year ended December 31, 2025, was $958.4 million, a 432% increase from $180.1 million in 2024, driven by increased demand for Rezdiffra and a full year of commercialization [448]. - Cost of sales for 2025 was $56.1 million, up 801% from $6.2 million in 2024, reflecting the same factors as product revenue [449]. - Research and development expenses increased to $388.5 million in 2025, a 64% rise from $236.7 million in 2024, primarily due to business development transactions [450]. - Selling, general and administrative expenses rose to $813.8 million in 2025, an 87% increase from $435.1 million in 2024, mainly due to increased commercial activities for Rezdiffra [451]. - Interest income decreased to $37.4 million in 2025 from $46.7 million in 2024, primarily due to higher principal balances and interest rates [452]. - Interest expense increased to $22.3 million in 2025, up 52% from $14.7 million in 2024, due to a higher average outstanding principal balance [453]. - For the year ended December 31, 2025, net cash used in operating activities was $189.6 million, primarily due to losses from operations [475]. - The company reported net cash provided by financing activities of $735.1 million for the year ended December 31, 2024, mainly from the 2024 Offering [480]. Product Development and Commercialization - Rezdiffra, the company's medication for MASH, was approved by the FDA in March 2024 and began generating revenue in April 2024 [419]. - The company launched Rezdiffra in Germany in September 2025, marking it as the first medication approved for noncirrhotic MASH with moderate to advanced liver fibrosis [419]. - The company plans to evaluate additional therapies to expand the eligible patient population for Rezdiffra [423]. - The company expects fluctuations in financial results based on net sales of Rezdiffra and the progress of research and development efforts [423]. - The company has acquired rights to several new drug candidates, including MGL-2086 and ervogastat, to enhance its pipeline for MASH treatment [420]. - The company received FDA approval for Rezdiffra in March 2024 and EC approval in August 2025, with a tiered royalty payable to Roche on net sales [484]. - In July 2025, the company entered into a license agreement with CSPC for MGL-2086, paying an upfront fee of $120.0 million and potential milestone payments of up to $2.0 billion [485]. Operational Expenses and Future Outlook - The company expects to incur additional operating losses due to planned expenditures for commercializing Rezdiffra and expanding operations in Europe [422]. - Research and development expenses are expected to remain substantial as the company conducts clinical trials and manufacturing studies [429]. - Selling, general and administrative expenses are anticipated to increase as the company expands its operations and commercialization efforts [433]. - The company anticipates continued losses until sufficient revenue is generated from Rezdiffra and other future products, with potential future capital needs for operations [457]. Financing and Cash Position - As of December 31, 2025, cash, cash equivalents, restricted cash, and marketable securities totaled $988.6 million, compared to $931.3 million in 2024 [455]. - The company entered into a Financing Agreement on July 17, 2025, providing up to $500.0 million in senior secured credit facilities [462]. - As of December 31, 2025, the outstanding principal under the Financing Agreement was $350.0 million, with an interest rate of 8.75% [467]. - The company has approximately $268.3 million in obligations related to agreements for active pharmaceutical ingredients as of December 31, 2025 [488]. - The company has not entered into any hedging arrangements for foreign currency risk as it expands operations into Europe [492]. - Inflation has not materially affected the company's financial condition or results of operations during the years ended December 31, 2025, 2024, or 2023 [494]. Public Offerings - In March 2024, the company completed a public offering, selling 750,000 shares at $260.00 per share and pre-funded warrants for 1,557,692 shares at $259.9999 each, raising approximately $659.9 million in net proceeds [468][469]. - The 2023 public offering closed on October 3, 2023, with gross proceeds of $500.0 million and net proceeds of approximately $472.0 million after expenses [471][472].